About Us
A team dedicated to revolutionizing precision-guided in vitro diagnostics
NeuroDetect is a biotechnology company developing FDA-compliant machine learning-guided software that will allow medical professionals to create precision-guided diagnostic and therapeutic biomarker profiles of patients suffering from neurological disorders.
We are proud to be a portfolio company for The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP), an FDA-funded pediatric medical device accelerator.
Our Team
Warren Merrifield, Ph.D.
Chief Executive Officer
Neuroscientist with experience building and leading research programs to diagnose and treat patients with epilepsy and traumatic brain injury (TBI).
At Walter Reed National Military Medical Center, built and led functional brain imaging program to diagnose and treat patients with TBI. Designed experiments, obtained regulatory approvals, awarded millions in funding, worked with all patients, and briefed hundreds of government and academic leaders.
During graduate school and as part of NIH-funded study, co-developed non-invasive language mapping protocol for epilepsy patients for more precise evaluation prior to neurosurgery.
Experimental Psychology Ph.D. from Loma Linda University; B.S. in Psychology and Anthropology from Colorado State University.
Gavin Kress, M.S.
Chief Technology Officer
Graduated Salutatorian of The University of Southern California (USC) with a B.S. in Biomedical Engineering and Minor in Physics. M.S. in Mechanical Engineering.
Varied research experience in the fields of epigenetics, biomedical engineering, medicine, neuroscience, molecular biology, and biophysics.
Broad knowledge base and skill set including software programming, hardware design and construction, engineering, mathematics, physics, chemistry, and more.
Extensive laboratory experience with cell culture, working with stem cells, and genetic engineering techniques such as CRISPR as well as a medical background as an EMT.
Founder and President of a nonprofit dedicated to fighting vaccine hesitancy and supporting vaccine research and global availability.
Taylor Takayoshi, M.S.
Chief Operating Officer
Graduated from the University of California, Irvine with a B.S. in Biomedical Engineering and M.S. in Biomedical Engineering from the University of California, Irvine through the Accelerated Master’s Program.
Research experience with in vitro models of cardiac development and function at the cellular, tissue, and organ level.
Laboratory experience in cell culture, tissue engineering, and microscopy.
Former Core Lab Manager at the Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center (CIRC) at UC Irvine.
Advisor
Richard Creager, Ph.D.
Advisor
Dr. Creager has more than 35 years of experience in the in vitro diagnostics (IVD) industry. During his career, he led the development and commercialization of more than 160 IVD products for infectious disease, cardiovascular disease, fertility, thyroid disease, autoimmune disease, cancer, and women’s health.
Currently, Dr. Creager is the founder of NaviDx LLC, a management consultant firm for IVD and biotechnology companies. He is a business consultant for the SBDC @UCI Beall Applied Innovation and an advisor to the National Institutes of Health (NIH) RADx, a fast-track program that supports the development and commercialization of innovative technologies to significantly increase the U.S. testing capacity for SARS-CoV-2, the virus that causes COVID-19.
Previously, Dr. Creager was the SVP Molecular Diagnostics and Chief Science Officer for Beckman Coulter. He served as Group Vice President for Beckman Coulter’s Immunoassay Business and held senior executive positions with Kallestad Diagnostics and Sanofi Diagnostics Pasteur. In addition, Dr. Creager served as chairman of the board for Medical Alley, a 501(c)3 non-profit trade association of healthcare companies in Minnesota. He currently serves on the board of directors for the 1for2 education foundation, OnRamp Bioinformatics, and Seraph Biosciences.
Dr. Creager has a B.S. from Muhlenberg College, a M.S. from Duquesne University, and a Ph.D. from the University of Pittsburgh School of Medicine. He also attended The Wharton School of Business for Advanced Management Program.